The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

AACR 2020 | The rationale of combining PD1 blockade with two epigenetic modifiers for T-cell lymphoma treatment

May 13, 2020

The Lymphoma Hub was pleased to speak with Enrica Marchi, Center for Lymphoid Malignancies, Columbia University Medical Center, New York, US.

Enrica Marchi explains the rationale for the combination of PD1 blockade with epigenetic modifiers and its activity in preclinical models and early phase clinical trials for peripheral T-cell lymphoma (PTCL) treatment. She discusses the results of two multicenter, multi-arm, international study clinical trials — the DURABILITY trial (NCT03161223) and the EMBOLDEN trial (NCT03240211) — that assessed the value of adding an immune checkpoint inhibitor to an epigenetic modifier backbone regimen for the treatment of PTCL. She talks about the patient characteristics, safety profile, and clinical responses of both trials.

The rationale of combining PD1 blockade with two epigenetic modifiers for T-cell lymphoma treatment